Coronavirus Stocks Seeing the Biggest Bounce Back
More and more companies are joining the fight against the coronavirus, and 24/7 Wall St. is taking a look at some of the biggest movers on the day tied to COVID-19.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 69
How Kala Pharma Is Surviving Monday’s Market Carnage
Kala Pharmaceuticals said that it had positive topline results from its late-stage clinical trial for the treatment of dry eye disease.
Over 15 Million Coronavirus Deaths Possible This Year
A global coronavirus pandemic could kill more than 15 million people worldwide in just one year and cause more than $2 trillion in lost economic growth.
Consumer Sentiment Stops Tumbling, Remains Low
Consumer sentiment on Wednesday stopped a tumble that began in mid-February. Thursday's stock market action could send the Morning Consult index lower again, however, as volatility continues to rule the day.
Amarin Stock Faces Sell-Off Crisis
Shares of Amarin have plunged in recent months. Even more troubling, there appears to no catalyst to drive them higher.
The Case for 2 Coronavirus Test Companies
More and more companies are joining the fight against the coronavirus. Quest Diagnostics is one of the newest to make this list.
Growing Business Optimism Hampered by Coronavirus Spread
While business leaders remain optimistic about economic prospects this year, the spread of the coronavirus is beginning to tamp down enthusiasm.
What Arcturus Therapeutics Brings to the Fight Against the Coronavirus
Arcturus Therapeutics stock jumped on Wednesday after the company announced that it would be joining the fight against the latest coronavirus.
Raymond James Makes Huge Changes to Health Care Top Picks List
Ranging from very conservative to aggressive, these Raymond James health care stock picks are good additions to long-term portfolios looking to add or increase exposure to the sector.
One Call Still Sees a Double-Your-Money Upside from the Peanut Allergy Treatment
Peanut allergy is a serious and dangerous, but one biotech may hold the answer that could lead to to a 100% or 200% gain as its peanut allergy drug is expected to become more…
Why Stealth BioTherapeutics FDA Update Is a Big Deal
Stealth Bio stock more than doubled on Tuesday after the company announced a critical update from the FDA.
Can Co-Diagnostics Dominate Coronavirus News Against New Competition
Co-Diagnostics is a small-cap stock that is far from a household name, but it has received much added exposure of late.
Tilray’s Q4 Up in Smoke
Tilray released fourth-quarter financial results after the closing bell on Monday. The company said that it had a net loss of $0.62 per share and $46.94 million in revenue, compared with consensus estimates that…
Beam Therapeutics Could See Over 40% Upside Despite Unlucky IPO Timing
The analysts at its underwriting firms are quite positive on Beam Therapeutics, now that its post-IPO quiet period has come to an end.
Is Gilead Overpaying for Forty Seven?
Forty Seven shares skyrocketed on Monday after the company announced that it would be acquired by Gilead Sciences. But is Gildead paying too much?